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Rationale: Varenicline, the most effective single agent for smoking cessation, is a
partial agonist at α4β2 nicotinic acetylcholine receptors. Increasing evidence implicates
glutamate in the pathophysiology of addiction and one of the benefits of treatment for
smoking cessation is the ability to regain cognitive control.
Objective: To evaluate the effects of 12-week varenicline administration on glutamate
levels in the dorsal anterior cingulate cortex (dACC) and functional changes within the
cognitive control network.
Methods:We used single-voxel proton magnetic resonance spectroscopy (1H-MRS) in the
dACC and functional MRI (fMRI) during performance of a Stroop color-naming task before
and after smoking cessation with varenicline in 11 healthy smokers (open label design).
Using the dACC as a seed region, we evaluated functional connectivity changes using a
psychophysiological interaction (PPI) analysis.
Results: We observed a significant decrease in dACC glutamate + glutamine (Glx)/Cr
levels as well as significant blood oxygen level-dependent signal (BOLD) decreases in the
rostral ACC/medial orbitofrontal cortex and precuneus/posterior cingulate cortex. These
BOLD changes are suggestive of alterations in default mode network (DMN) function
and are further supported by the results of the PPI analysis that revealed changes in
connectivity between the dACC and regions of the DMN. Baseline measures of nicotine
dependence and craving positively correlated with baseline Glx/Cr levels.
Conclusions: These results suggest possible mechanisms of action for varenicline such
as reduction in Glx levels in dACC and shifts in BOLD connectivity between large scale
brain networks. They also suggest a role for ACC Glx in the modulation of behavior. Due
to the preliminary nature of this study (lack of control group and small sample size), future
studies are needed to replicate these findings.
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INTRODUCTION
Varenicline is an α4β2 nicotinic acetylcholine receptor (nAChR)
partial agonist (Rollema et al., 2007) that is more efficacious than
nicotine replacement therapies or bupropion for smoking ces-
sation (Gonzales et al., 2006) but still only results in smoking
cessation rates of 25–30% 6 months after treatment (Tonstad
et al., 2006). Thus, while varenicline is the single best agent
currently available, new medications are needed for smoking ces-
sation treatment. Apart from its action at nAChR, little is known
about the mechanism of action of this drug. It is critical to
understand the mechanism of action of varenicline so that more
effective smoking cessation drugs can be developed.
Increasing evidence implicates glutamate in the
pathophysiology of addiction (Kalivas et al., 2009), including
nicotine addiction (Markou, 2008). Preclinical research in animal
models of nicotine-dependence indicates that reducing gluta-
matergic transmission through pharmacological manipulations
decreases the rewarding effect of nicotine (Paterson et al., 2003;
Paterson and Markou, 2005). Furthermore, pre-clinical animal
research indicates varenicline may act on glutamate levels by
increasing glutamic acid decarboxylase expression in prefrontal
cortex (Maloku et al., 2011). In humans, measures of central glu-
tamate levels can be obtained using proton magnetic resonance
spectroscopy (1H-MRS). Specifically, prior MRS studies suggest
a role for ACC glutamate levels in the modulation of addiction
behaviors. A recent MRS study in alcohol-dependent subjects
(Umhau et al., 2010) found a reduction of glutamate levels in the
anterior cingulate cortex (ACC) following a 4-week treatment
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with acamprosate, a drug approved for the maintenance of
alcohol dependence. Similarly, a positive correlation was found
between alcohol craving and rostral ACC Glx levels in alcohol-
dependent patients immediately after detoxification (Bauer
et al., 2013). Changes in ACC glutamate after administration
of varenicline might suggest a mechanism by which the drug
decreases addiction. However, there have been no prior MRS
studies of pharmacologically supported smoking cessation.
A number of functional magnetic resonance imaging (fMRI)
studies have been conducted investigating the effects of vareni-
cline; they suggest that the drug diminishes physiological
responses that lead to relapse such as smoking cue reactivity
(Franklin et al., 2011) and the mental disturbances experienced
during withdrawal (Loughead et al., 2010; Sutherland et al.,
2013). One of the long term benefits of treatment for smoking ces-
sation is the ability to regain control over smoking cues. Several
imaging studies indicate that cognitive control, or the ability to
shift the processing of perceptual information toward relevant
goals, is impaired in addiction (Harding et al., 2012). Azizian et al.
(2010) showed that nicotine modulates the blood oxygen level
dependent (BOLD) response in regions of the cognitive control
network (CCN) (Niendam et al., 2012). On the other hand, inves-
tigation of the effects of nicotine on functional connectivity (FC),
a measure of temporal coherence of spontaneous neural activity
between brain regions, reported changes in FC with regions of
the default mode network (DMN) (Raichle and Snyder, 2007), a
neural network associated with rest and independent of task or
external stimuli (Mason et al., 2007). Since acute administration
of nicotine changes the FC between regions of the CCN andDMN
(Cole et al., 2010), we were interested in assessing the effect of
varenicline on BOLD response and FC between networks.
The aim of this study was to investigate the effect of a 12
week smoking cessation therapy with varenicline on glutamate
levels and cognitive control function. We acquired single-voxel
1H-MRS measurements in the dorsal ACC (dACC) to obtain glu-
tamate measurements. To activate the CCN, we chose a Stroop
color-naming task, which has been shown to produce robust acti-
vation in the dACC during high-conflict trials (Azizian et al.,
2010). To investigate CCN FC during the Stroop, we conducted
a psychophysiological interaction analysis with the dACC as seed
region. On the basis of the existing literature (Markou, 2008;
Kalivas et al., 2009; Azizian et al., 2010; Cole et al., 2010), we
hypothesized that dACC glutamate + glutamine (Glx) levels
would decrease and dACC BOLD signal and connectivity would
be altered after treatment with varenicline. Finally, to explore
patterns that would predict adherence to smoking cessation ther-
apy, we contrasted glutamate levels and BOLD response between
those who completed the study and those who dropped out after
completing the baseline scanning session.
MATERIALS AND METHODS
PARTICIPANTS
We recruited 22 adult participants (age 19–65) who smoked at
least 10 cigarettes per day (cpd) and desired smoking cessa-
tion treatment via advertisements in flyers and the University
of Alabama at Birmingham (UAB) newspaper. Exclusion crite-
ria were major medical conditions, substance abuse other than
nicotine within 6 months prior to enrollment, previous seri-
ous head injury, a neurologic disorder, loss of consciousness for
more than 2min, and pregnancy. The UAB Institutional Review
Board approved the study, and all participants provided written
informed consent prior to enrollment.
Participant smoking history, cpd, and measures of nicotine
dependence, withdrawal, and craving were assessed weekly for the
first 4 weeks and at the 12th week using the Fagerström Test for
Nicotine Addiction (FTND) (Heatherton et al., 1991), Minnesota
Nicotine Withdrawal Scale (M-NWS; 7 items following DSM-IV
criteria for nicotine withdrawal) (Hughes and Hatsukami, 1986),
and the Questionnaire of Smoking Urges Short Form (QSU-brief;
10 item measure of craving) (Cox et al., 2001). Common side
effects associated with the use of pharmacotherapy and quitting
smoking were assessed using the Symptoms and Side Effects ques-
tionnaire (SSE; 30 items) (Markou, 2008). Depressive symptoms
were assessed using the Center for Epidemiological Studies on
Depression Scale (CES-D; 20 item self-report measuring depres-
sion) (Radloff, 1977), and the Sensitivity to Punishment and
Sensitivity to Reward Questionnaire (SPSRQ) (Torrubia et al.,
2001) was administered to determine the valence of external
rewards and punishments. Expired air carbon monoxide (CO)
concentration in parts per million was measured by a Vitalograph
BreathCO monitor (Vitalograph, Inc., Lenxa, KS) once a week
for the first 4 weeks as well as prior to the second scan and
used in combination with participant cpd self-report to con-
firm smoking status. Smokers were allowed to smoke up to 1 h
before the scanning session to avoid nicotine intoxication or
withdrawal.
STUDY DESIGN AND PHARMACOLOGICAL INTERVENTION
Participants were scanned at baseline and after 12 weeks
of treatment with varenicline. Following the first scan, par-
ticipants completed 4 weekly sessions of a modified ver-
sion of the individual-based Tobacco Dependence Treatment
Program (ACT) (Payne and Crews, 2012) and were given daily
manufacturer-recommended dosing of varenicline (Pfizer Global
Pharmaceuticals, New York, NY). Dosing schedule consisted of
0.5mg for the first 3 days, 0.5mg twice daily for the next 4
days, and 1.0mg twice daily for the next 12 weeks. Nine par-
ticipants dropped out after the first scanning session, and two
participants dropped out after the first ACT session. Two of the
participants who dropped out were excluded from baseline fMRI
analyses due to missing behavioral responses during the task, and
one revoked consent. Eleven participants remained in the study
completing all four ACT sessions. Participant compliance was
checked using pill counting on a weekly basis. These 11 partic-
ipants were scanned within 1 week following the completion of
the varenicline regimen.
IMAGING PARAMETERS
All imaging was performed on a 3T single channel trans-
mit receive head-only Siemens Magnetom Allegra scanner.
fMRI data were acquired using a gradient recalled echo-
planar imaging (EPI) sequence (repetition time/echo time
[TR/TE] = 2100/30ms, flip angle = 70◦, field of view = 24 ×
24 cm2, 64 × 64 matrix, 4-mm slice thickness, 1-mm gap, 26 axial
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slices). A three-dimensional T1-weightedmagnetization prepared
rapid acquisition gradient-echo sequence (MP-RAGE) structural
scan with 1-mm isotropic voxels was acquired for anatomical
reference (TR/TE/TI = 2300/3.93/1100ms, flip angle = 12◦,
256 × 256 matrix).
1H-MRS
A 1H-MRS voxel was placed in the bilateral dACC as described
previously (Reid et al., 2010). Manual shimming was performed
to optimize field homogeneity across the voxel, and chemical shift
selective pulses were used to suppress the water signal. Spectra
were acquired using the point-resolved spectroscopy sequence
(PRESS; TR/TE = 2000/80ms to optimize the glutamate signal
and minimize macromolecule contribution, number of aver-
ages = 256, scanning time = 8min 32 s; voxel size 2.7 × 2 ×
1 cm3) (Bottomley, 1987). MRS data were analyzed in jMRUI
(version 3.0) (see Methods in Reid et al., 2010). Briefly, the model
consisted of peaks for N-acetyl aspartate (NAA), choline (Cho),
creatine (Cr), and three peaks for glutamate + glutamine (Glx).
NAA, Glx, and Cho were quantified with respect to Cr. Only Glx
peaks are reported and discussed in this study. The MRS voxel
was positioned on an individual basis at baseline and week 12 to
maximize gray matter based on cortical landmarks. Of the partic-
ipants who did complete the study, one participant did not have
post-varenicline MRS spectra, leaving 10 study completers with
MRS spectra pre- and post-varenicline.
fMRI
An IFIS-SA system running E-Prime software (1.2; Psychology
Software Tools, Pittsburgh, Pennsylvania) was used to control
stimulus delivery and to record button press responses and
reaction times. Participants performed a version of the Stroop
color-naming task as described previously (Reid et al., 2010).
Stimuli were three words, “RED,” “GREEN,” or “BLUE,” printed
in one of those three colors. Incongruent trials were those in
which the word and color were different. Participants were
instructed to indicate the color of the word and ignore the
meaning of the word. The experiment consisted of three runs
of 88 trials. The 3 second trials comprised a word stimulus
for 1.5 seconds and a fixation cross for 1.5 seconds. fMRI data
analyses were implemented in SPM8 (Wellcome Trust Centre for
Neuroimaging). Preprocessing of the fMRI data included slice
timing correction, motion correction using ArtRepair (0.5mm
cutoff; CIBSR Stanford University, CA), reslicing to 2-mm
isotropic voxels, coregistration to the baseline structural scan,
smoothing with a 4mm full width at half maximum Gaussian
kernel, and DARTEL normalization to a group template brain
and then standard Montreal Neurological Institute space to
facilitate between-subjects comparison (Ashburner, 2007). No
subjects were excluded based on movement.
STATISTICAL ANALYSES
Behavior
All behavioral scales and responses were analyzed in PASW
Statistics 18 (IBM SPSS Inc., Chicago, IL). Comparisons between
groups on smoking and other behavioral measures were done
using chi-square and analysis of variance (ANOVA) procedures,
as appropriate. Paired t-tests were used to examine change across
the two time points. The Stroop effect was defined as mean reac-
tion time during congruent trials subtracted from mean reaction
time during incongruent trials.
MRS
Independent samples t-tests were used to assess Glx/Cr at baseline
between study completers and study non-completers. A paired
samples t-test was used to assess the change in Glx/Cr from
baseline to week 12 in study completers.
fMRI
Statistical tests involved two levels, the single-subject level (fixed
effects) and the group level (random effects). At the first level, sta-
tistical analyses of fMRI data consisted of a single-subject voxel-
by-voxel general linear model. Five conditions were included in
themodel including incongruent trials, congruent trials, error tri-
als, no response trials, and stimulus repetitions (defined as any
trial that was an exact repetition of the previous trial) (Reid et al.,
2010). Conditions were convolved with the canonical hemody-
namic response function with a temporal derivative. Statistical
parametric maps (SPMs) were generated for the contrast of cor-
rect incongruent trials minus correct congruent trials (Stroop
effect). These contrasts were then used at the second level. One
sample t-tests were used to assess the group mean differences in
the Stroop effect at baseline and after treatment with varenicline.
A paired samples t-test was used to make comparisons between
the two time points. Additionally, CO was added to analyses at
the second level as a covariate of no interest to account for dif-
ferential effects of nicotine. Results were not substantially altered
by adding this covariate. All images were set at a statistical sig-
nificance threshold of p < 0.05 with family-wise error (FWE)
cluster-level correction. To assess the possibility of type II error
due to the small sample size, effect size (Cohen’s d) was calculated
voxel-wise for the paired samples comparisons of fMRI data.
Psychophysiological interaction (PPI)
Modulatory interactions using a dACC seed region were assessed
using the PPI toolbox in SPM8 (Friston et al., 1997). The PPI anal-
ysis consists of a design matrix with three regressors: the “psycho-
logical variable” in this case the Stroop effect (correct incongruent
trials—correct congruent trials), the “physiological variable” rep-
resenting the signal time course in the seed region (anterior
dACC), and a variable representing the interaction of the two pre-
vious terms—the psychophysiological interaction. The anterior
dACC was defined as one slice forward from the disappearance
of the juncture of the anterior corpus callosum from both hemi-
spheres and the posterior end as the first vertical slice posterior to
the anterior commissure. Using this structurally defined region
of interest (ROI), a time series from the anterior dACC was
extracted from each participant’s contrast for the Stroop Effect
condition. SPMs were thresholded at p < 0.05 to ensure the pres-
ence of BOLD signal in all participants. A variable representing
the interaction term between each time series and the psycholog-
ical variable (Stroop effect) was constructed for each participant.
Subject-specific contrast images representing functional connec-
tivity of the anterior dACC during Stroop were then entered into a
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paired samples t-test in order to assess differences in connectivity
between baseline (pre-varenicline) and week 12 (post varenicline)
(see Figure 2, Table 4). FWE cluster-level correction (p < 0.05)
was applied to all group-level contrasts.
Exploratory analyses
Pearson’s correlations were used to assess the relationship between
dACC Glx and smoking related measures including nicotine
dependence (FTND) and nicotine craving (QSU-sf). Bonferroni
correction was applied to all correlations.
Study completers vs. study non-completers
We compared study completers and those who dropped out
after the baseline scan on baseline characteristics, Glx and BOLD
response. T-tests were performed to assess differences on smok-
ing parameters and dACC Glx. BOLD differences were assessed
during the Stroop effect at baseline using SPM8 (p < 0.05 FWE
cluster level corrected).
RESULTS
Seven of the 11 study completers (64%) stopped smoking
entirely with the other four participants significantly decreas-
ing their cigarette consumption [pre-varenicline cpd M = 27.50,
SD = 15.00 to post-varenicline cpd M = 5.50, SD = 6.40,
t(3) = 3.26, p = 0.047]. Study completers had significantly lower
craving (QSU-sf) scores at week 12. Symptoms of withdrawal
(MNWS), sensitivity to reward (SPSRQ), depression (CESD),
and symptoms (SSE) did not significantly change pre- to post-
varenicline treatment (Table 1).
BEHAVIORAL
There were no significant changes in Stroop effect reaction time
nor differences in number of errors pre-to-post varenicline.
Reaction time on congruent trials was significantly faster at the
post-varenicline scan (Table 1).
MRS
Study completers had significantly higher Glx/Cr pre-varenicline
than post-varenicline (see Table 2, Figures 1A,B). Cr did not
significantly differ pre- to post-varenicline t(9) = −0.889,
p = 0.397.
fMRI
Within-group at baseline and week 12 t-tests as well as between
baseline and week 12 paired t-tests of the BOLD during the
Stroop Effect are presented in Figures 2A–C. Regions including
the anterior cingulate, bilateral anterior insula/frontal opercu-
lum, right supramarginal/angular gyri, and bilateral dorsolat-
eral prefrontal cortex were identified as significantly activated
during incongruent-congruent contrasts in both pre- and post-
varenicline scans (Figures 2A,B, Table S1). These regions are
those typically activated with the Stroop task (Botvinick et al.,
1999) and are consistent with activation of the CCN (Niendam
et al., 2012). In post-varenicline scans, a significant deactiva-
tion can be seen in the rostral ACC extending into the medial
orbitofrontal cortex (mOFC), as well as deactivation in the mid-
dle cingulate, precuneus, and left temporal lobe (Figure 2B).
Deactivation in the post-varenicline scan drove the significant
Table 1 | Study Completers: Behavioral and Clinical Measures.
Characteristic Baseline Week 12 t-value p-value
(Pre-drug) (Post-drug)
SMOKING BEHAVIOR
CO* 19.27±8.48 4.36±5.70 6.71 <0.001
CPD 23.60±9.20 2±4.4 9.01 <0.001
STROOP TASK BEHAVIOR
Congruent RT 799±14 762±9 2.36 0.04
Incongruent RT 956±17 918±13 1.73 0.12
Stroop effect RT 154±8 158±6 −0.29 0.78
Task errors 4.36±2.94 11.27±18.00 −1.24 0.24
CLINICAL MEASURES**
FTND 5.89±2.0 – – –
MNWS 9.22±5.61 6.00±6.67 1.04 0.33
QSU-brief 39.11±15.37 11.89±3.52 4.54 0.002
SPSRQ 14.44±5.92 16.44±7.59 −1.73 0.12
CESD 9.67±4.24 9.33±4.64 0.23 0.83
SSE 45.44±12.07 38.67±8.02 1.64 0.14
CESD, Center for Epidemiological Studies on Depression; CO, carbon monox-
ide; CPD, cigarettes per day; FTND, Fagerström Test for Nicotine Addiction;
MNWS, Minnesota Nicotine Withdrawal Scale (Hughes-Hatsukami Withdrawal
Scale); RT, reaction time in milliseconds; SPSRQ, Sensitivity to Punishment and
Sensitivity to Reward Questionnaire; SSE, Symptoms and Side Effects; QSU-
brief Questionnaire of Smoking Urges Short Form.
FTND week 12 scores have been omitted. Two of the seven items on the FTND
are related to recent smoking behavior. Because subjects are enrolled in a study
to reduce smoking behavior, reduced scores on this measure may reflect behav-
ioral changes and not nicotine dependence per se.
*scores imputed for two participants.
**scores missing for two participants.
Table 2 | Glutamate Measurement in Dorsal Anterior Cingulate
Cortex.
Metabolite Baseline Week 12 t-value p-value
completers completers
Glx/Cr 0.705±0.089 0.646±0.045 2.743 0.023
CRLB ± SD 7.1±1.7% 6.9±1.5%
(CRLB Range) (5.8–11.6%) (5.4–10.2%)
Cr, creatine; CRLB, Cramer-Rao Lower Bounds; Glx, glutamate + glutamine.
There were no significant differences in the raw amplitude of Cr between base-
line (pre-drug) and week 12 (post-drug) t(9) = −0.889, p = 0.397. There were
no significant differences between baseline to week 12 in metabolite peak line
width, CRLBs, gray matter voxel content, or white matter voxel content.
decreased activation in the rostral ACC/mOFC and precuneus
seen in the post > pre-varenicline contrast (Figure 2C, Table 3).
No regions survived cluster level correction in week 12> baseline
contrasts. Effect size calculation for contrast of post > pre-
varenicline showed medium to large effect size across many areas
of the brain (Figure S1).
PPI
Voxelwise PPI connectivity with the dACC seed region is pre-
sented in Figure 2D. At baseline and week 12, only regions
Frontiers in Pharmacology | Neuropharmacology July 2014 | Volume 5 | Article 158 | 4
Wheelock et al. Varenicline effects on cingulate cortex
FIGURE 1 | Dorsal anterior cingulate (dACC), glutamate + glutamine
(Glx)/creatine (Cr), baseline (pre-drug), and at week 12 (post-drug)
for study completers. (A) Box plot of median Glx/Cr in the dACC at
baseline and week 12. (B) Line plot of individual Glx/Cr in the dACC
at baseline and week 12. Asterisk indicates significant t-statistic at
p < 0.05.
negatively correlated with the dACC seed region survived sta-
tistical thresholding (Figures 2D,E). Regions including bilateral
superiormedial frontal, rostral ACC, precuneus, middle, and pos-
terior cingulate were significantly negatively correlated with the
dACC seed region at baseline (Figure 2D). At week 12, dACC
was negatively correlated with sensory motor area, bilateral infe-
rior, and superior parietal lobe, precuneus, middle occipital lobe,
thalamus, and temporal gyrus (Figure 2E, Table S2). Bilateral
medial superior frontal, bilateral rostral ACC, as well as, bilat-
eral posterior and middle cingulum, and bilateral precuneus were
significantly more negatively correlated at baseline than at week
12 (Figure 2F, red). Bilateral inferior parietal and right superior
occipital were significantly more negatively correlated at week 12
than baseline (Figure 2F blue, Table 4).
EXPLORATORY ANALYSES
A positive correlation was found between baseline nicotine
dependence (FTND) and baseline Glx/Cr (Figure 3A) as well
as between baseline nicotine craving (QSU-sf) and baseline
Glx/Cr (Figure 3B). At baseline, degree of nicotine dependence
(Figure 3B) and nicotine craving (Figure 3B) positively correlates
with amount of Glx/Cr in the dorsal cingulate. Due to the small
sample size and inherent floor effects of the FTND and QSU-
sf, post-varenicline nicotine dependence and nicotine craving did
not correlate with post-varenicline Glx/Cr.
STUDY COMPLETERS vs. STUDY NON-COMPLETERS
There were no significant differences between study completers
and those who dropped out after the baseline scan on demo-
graphics, Stroop effect, smoking behavior, history, or clinical
scales (Table 5). Baseline Glx/Cr was not significantly differ-
ent between study non-completers (n = 11) and study com-
pleters (n = 10) t(19) = 0.217, p > 0.05 (Table S4). Subcortical
regions including the striatum and thalamus, as well as, cortical
regions including bilateral insula, left temporal gyrus, and left
middle and inferior frontal gyri were significantly more active
at baseline in study non-completers than in study completers
(Figure 4, Table S3).
DISCUSSION
The aim of this study was to evaluate the effects of 12 week
varenicline administration on Glx/Cr in the dorsal ACC (dACC)
and functional changes within the CCN. Following treatment we
observed a significant decrease in dACC Glx/Cr levels, as well as,
significant BOLD decreases in the rostral ACC (rACC)/mOFC
and precuneus/posterior cingulate cortex (PCC). These BOLD
changes are suggestive of alterations in DMN function, and are
further supported by the results of the PPI analysis that revealed
changes in FC between the dACC and regions of the DMN.
Baseline measures of nicotine dependence and craving positively
correlated with baseline Glx/Cr levels. Finally, at baseline, study
non-completers had significantly more task activation in the ven-
tral striatum, thalamus, and insular cortex than study completers.
To our knowledge there have been no previous MRS studies
of pharmacologically supported smoking cessation. As hypoth-
esized, we observed a significant decrease in dACC Glx/Cr lev-
els after treatment (Figure 1A). This 8.7% Glx decrease is in
the range of that observed with the use of memantine, an N-
methyl-D-aspartate (NMDA) antagonist used for the treatment
of Alzheimer’s disease (van Wageningen et al., 2010). In a group
of active smokers, Gallinat and colleagues found that dACC Glx
levels were not significantly different than those of non-smokers
or former smokers (Gallinat and Schubert, 2007). These data
suggest the Glx decrease seen in this study cannot be inter-
preted as normalizing Glx levels from an increased state and
point toward a drug effect. These results concur with preclin-
ical research showing that reducing glutamatergic transmission
through pharmacological manipulations decreases the rewarding
effect of nicotine (Markou, 2008) and suggest a mechanism by
which varenicline improves abstinence.
To investigate the relationship between glutamate and nicotine
addiction we correlated a measure of baseline nicotine depen-
dence (FTND total score) and baseline craving (QSU-sf) with
baseline Glx/Cr. Both nicotine dependence and craving were sig-
nificantly and positively correlated with Glx levels (Figures 3A,B).
Interestingly, positive correlations between craving and ros-
tral ACC Glx levels in alcohol-dependent patients immediately
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FIGURE 2 | Stroop task BOLD contrasts and Psychophysiological
Interaction (PPI) analysis results. Group BOLD activation (red) and
deactivation (blue) maps shown for BOLD at baseline scans pre-drug (A),
BOLD for week 12 scan post-drug (B), and BOLD Post>Pre-drug (C) as well
as PPI for baseline scan pre-drug (D), PPI post-drug (E), and PPI
Post>Pre-drug (F). All color intensities are voxel-wise t-statistics with
significance p < 0.05 FWE cluster-level correction. Activation maps are
overlaid onto the averaged anatomical scan Colin27 in MRIcron and are
displayed in neurological view (left is on the viewer’s left). (1) Supplementary
Motor Area (SMA); (2) Inferior Frontal Gyrus; (3) Insula; (4) Middle Temporal
Gyrus; (5) rostral ACC connected to medial orbitofrontal cortex; (6) Posterior
Cingulate; (7) Inferior Parietal; (8) Thalamus.
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Table 3 | Areas with Significant Changes in BOLD Signal for the
contrast incongruent greater than congruent following smoking
cessation therapy with varenicline.
Region Hem x, y, z Cluster peak
size t-Value
BASELINE>WEEK 12
Anterior cingulum L −5, 48, 0 840 7.76
Cluster sub regions
Anterior cingulum R 404
Middle cingulum R 229
Precuneus R 430
Caudate L 203
Superior frontal R 159
Medial sup frontal L, R 819, 279
Medial OFC L, R 324, 152
Middle temporal L −50, −41, 12 339 6.51
Hem, hemisphere; OFC, Orbitofrontal Cortex; SMA, Supplementary Motor Area;
x, y, z refers to Montreal Neurological Institute coordinates. All regions are sig-
nificant at a cluster level threshold of p < 0.05 FWE cluster level corrected. No
regions survived thresholding in Week 12 > Baseline contrast. See Table S1 for
within group results.
after detoxification (Bauer et al., 2013) and between impulsiv-
ity and dorsal ACC Glx (Hoerst et al., 2010) have been reported.
Collectively, these data suggest a role for ACC glutamate in the
modulation of behavior. In addition, thalamic Glx/Cr was found
to be higher in patients suffering from restless legs syndrome
(RLS) (Allen et al., 2013), and case report found RLS amelioration
with varenicline treatment (Romigi and Vitrani, 2013), suggesting
a potential mechanism whereby varenicline may reduce thalamic
Glx levels in these patients.
After treatment, we observed significant BOLD decreases in
rACC/mOFC and precuneus/PCC (Figure 2C). These results
show similarities to previous imaging studies with varenicline.
After 3 days of nicotine abstinence, while on varenicline, working
memory-related brain activity was increased, especially at higher
task difficulty, and was associated with improved cognitive per-
formance (Loughead et al., 2010). Interestingly, a whole-brain
analysis of this study revealed enhanced deactivations of PCC and
rACC in association with varenicline. In non-abstinent smok-
ers, 3 weeks of varenicline administration resulted in a decreased
response to smoking cues in the ventral striatum and mOFC
(Franklin et al., 2011). Further, abstinent smokers and non-
smokers demonstrated decreased resting state DMN connectivity
with the insula after 17 days of varenicline (Sutherland et al.,
2013). Thus, similar to our results, these studies found alterations
in regions of the DMN in association with smoking cessation with
varenicline. In this study, these alterations were observed in the
face of unchanged task performance.
We evaluated changes in FC during task performance using
PPI analysis. Prior to treatment, there was a significant nega-
tive FC between the dACC seed and the rACC and PCC, both
regions of the DMN (Figure 2D). Activities in the CCN and
the DMN have been shown to be negatively related (Fox et al.,
2005) so that during task performance the DMN is deactivated in
Table 4 | Changes in dACC functional connectivity for the contrast
incongruent greater than congruent following smoking cessation
therapy with varenicline.
Region Hem x, y, z Cluster peak
size t-Value
BASELINE>WEEK 12
Inferior parietal R 36, −47, 45 655 7.69
SupraMarginal gyrus R 279
Superior occipital R 33, −72, 42 300 6.37
Angular gyrus R 252
Superior parietal R 237
Inferior parietal L −18, −72, 45 549 5.41
Superior parietal L 403
WEEK 12 > BASELINE
Superior medial frontal R 17, 48, 5 389 7.88
Anterior cingulum R, L 202, 134
Superior frontal R 190
Superior medial frontal L 124
Superior orbitofrontal R 110
Posterior cingulum L −8, −24, 29 245 5.73
Middle cingulum L 245
Precuneus R, L 175, 170
Posterior cingulum R 117
Hem, hemisphere; x, y, z refer to Montreal Neurological Institute coordinates. All
regions are significant at a cluster level threshold of p < 0.05 FWE cluster level
corrected.
proportion to CCN activation. The loss of this negative coupling
appears to interfere with proper task performance (Sonuga-Barke
and Castellanos, 2007) while greater negative coupling is usually
regarded as advantageous in allocating cognitive resources during
task (Kelly et al., 2008). Our pre-varenicline results replicate pre-
vious findings of negative functional coupling between the CCN
and DMN regions.
Recent studies have reported greater deactivation of the DMN
with acute nicotine administration that was associated with
improved task performance (Hahn et al., 2007; Ettinger et al.,
2009). Furthermore, during resting state fMRI, acute nicotine
administered to abstinent smokers increased the negative FC
between CCN and DMN networks, an effect associated with
improvement in withdrawal symptoms (Cole et al., 2010). In
this study, after varenicline, the negative FC between the CCN
seed and the DMN was reduced while there was an increased
negative FC between the seed and the bilateral inferior parietal
cortex (Figure 2F). Increased connectivity between a dACC seed
region and parieto-occipital cortex has been found to distin-
guish cannabis users from controls in an emotional color word
Stroop (Harding et al., 2012). The parieto-occipital attention
network plays a role in selecting relevant objects and directing
appropriate behaviors (Hopfinger et al., 2000). The role of the
dACC has been ascribed to direct attention based on behav-
iorally relevant stimuli (Weissman et al., 2005). Thus, increased
negative FC between dACC and regions of the fronto-parietal
network may suggest changes in attentional bias toward drug
related stimuli. In contrast to studies of the acute effects of
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FIGURE 3 | Baseline scales of nicotine dependence (FTND) and nicotine
craving (QSU-sf) correlate with baseline dACC Glx/Cr. (A) Correlation of
Fagerström Test for Nicotine Addiction (FTND) and Glx/Cr: R2 = 0.558,
Pearson r = 0.747, p = 0.002 two-tailed, significant after Bonferroni
Correction (B) Questionnaire of Smoking Urges Short Form (QSU-sf),
R2 = 0.458, Pearson r = 0.677, p = 0.008 two-tailed, significant after
Bonferroni Correction. Two completers and five non-completers are missing
FTND and QSU-sf data, and one non-completer is missing Glx, leaving a
baseline group of 13 participants. FTND and QSU-sf scores were not
significantly correlated r = 0.378 p = 0.165.
Table 5 | Baseline Characteristics of Study Participants.
Both groups (n = 22) Study completers (n = 11) Study non-completers (n = 11) t/χ2 p-value
DEMOGRAPHICS
Gender M, F 10/12 4/7 6/5 0.73 0.39
Race C, AA 17/5 8/3 9/2 0.23 0.61
Age 36.32±11.86 36.0±11.19 36.64±13.03 −0.12 0.90
Educationa 2.91±0.68 3.09±0.54 2.73±0.79 1.27 0.22
Parental occupationb 7.36±5.02 6.0±3.92 8.73±5.78 −1.30 0.21
SMOKING BEHAVIOR
CO* 18.87±9.05 19.27±8.48 17.75±11.84 0.28 0.79
CPD 24.60±8.60 23.60±9.20 25.40±8.20 −0.49 0.63
SMOKING HISTORYc
Years of smoking 22.46±14.09 18.06±12.67 28.33±14.80 −1.40 0.19
Age daily smoker 17.36±2.74 17.88±2.53 16.67±3.08 0.81 0.44
Prior quit attempts 3.71±3.83 4.88±3.56 2.17±3.92 1.35 0.20
SMOKING SCALESd
FTND 5.80±2.27 5.89±2.21 5.67±2.58 0.18 0.86
M-NWS 9.87±6.63 9.22±5.61 10.83±8.42 −0.45 0.66
QSU-brief 33.93±19.19 39.11±15.37 26.17±23.06 1.31 0.21
SPSRQ 14.94±8.28 16.70±9.06 12.0±6.45 1.11 0.29
CESD 9.67±4.69 9.67±4.24 9.67±5.72 0.00 1.00
SSE 40.07±15.60 45.44±12.07 32.0±17.84 1.75 0.10
AA, African American; C, Caucasian; CESD, Center for Epidemiological Studies on Depression; CO, carbon monoxide; CPD, cigarettes per day; F, Female; FTND,
Fagerström Test for Nicotine Addiction; M, Male; M-NWS, Minnesota Nicotine Withdrawal Scale (Hughes-Hatsukami Withdrawal Scale); SPSRQ, Sensitivity to
Punishment and Sensitivity to Reward Questionnaire; SSE, Symptoms and Side Effects; QSU-brief, Questionnaire of Smoking Urges Short Form.
aEducation was scored on a scale from 1 to 4; (1) completed kindergarten through 8th grade; (2) 9th grade through highschool graduate; (3) some college through
college graduate; (4) postgraduate education.
bRanks determined from the Diagnostic Interview for Genetic Studies (1–18 scale); higher rank (lower numerical value) corresponds to higher socioeconomic status.
cBaseline scores are missing for nine participants.
dResponses are missing for seven participants.
*Scores imputed for seven study completers and two study non-completers.
nicotine on the DMN (Hahn et al., 2007; Ettinger et al., 2009),
the changes in FC reported here were observed after treat-
ment, at a time when participants did not experience symptoms
of withdrawal or craving, and most of them had stopped
smoking. Based on these observations, we have hypothesized
that changes in brain network dynamics are key to under-
standing the mechanism of sustained action of antismoking
drugs.
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FIGURE 4 | Baseline BOLD for Study Completers vs. Study Non-completers. All color intensities are voxel-wise t-statistic, p < 0.05 FWE cluster-level
corrected. Other conventions as in Figure 1. (1) Putamen; (2) Insula.
Nicotine addiction has been linked to its ability to release
dopamine through activation of α4β2 nAChRs located on pre-
synaptic neurons of the mesolimbic dopamine system (Benowitz,
2008). Smoking-induced increase in dopamine release produces
changes in synaptic plasticity (Kalivas and O’Brien, 2008) that
reinforce smoking behavior (Fiore et al., 2008) a process lead-
ing to addiction. Thus, it is possible varenicline affects the rACC
and mOFC through its action on mesolimbic dopaminergic neu-
rons. Speculatively, BOLD changes in these regions could trigger
concomitant changes in other regions of the DMN, including the
PCC.
While Mashhoon et al. (2011) found that higher Glx/Cr in
smokers predicted those who would relapse into smoking, we did
not find that Glx/Cr differentiated study completers and non-
completers. Perhaps one of the more interesting findings from
this study is that treatment completers and non-completers did
not differ in demographic and clinical characteristics, but did dif-
fer in that non-completers had increased baseline fMRI BOLD
intensities in the putamen and insula (Figure 4). Such a finding
could be an important clue for future work to help clarify the neu-
robiological substrates of treatment failure in smoking cessation,
especially since these findings appear to be better predictors than
any clinical or demographic information available. Converging
evidence links the ventral striatum to reward processing (Koob
and Volkow, 2010), our results point toward differences in acti-
vation of the reward system between the two groups. The role of
the insula has been linked to the monitoring of internal bodily
states and to the processing of subjective feelings (Craig, 2002,
2009). The insula and connected networks appear to play a critical
role in addiction, including nicotine addiction (Naqvi et al., 2007;
Sutherland et al., 2012). Importantly, damage to the insula, such
as in stroke, can disrupt nicotine addiction (Naqvi et al., 2007). In
addition, activity in the insula correlates with cue-induced drug
urges (Brody et al., 2002).
Our study has several limitations. The study was not placebo
controlled, and the design did not allow disentangling the effects
of smoking cessation and varenicline. This study design also did
not allow an assessment of potential practice effects due to par-
ticipants completing the Stroop again, 12 weeks later. Because
cerebral blood flow (CBF) can influence the BOLD signal (Kim
and Ogawa, 2012), and because varenicline alters CBF (Franklin
et al., 2011), it is possible that the observed changes in BOLD acti-
vation and connectivity were influenced by changes in CBF.While
this study controlled for false positive rates in the fMRI results
with FWE correction, the small sample size may lead to false
negatives. Furthermore, the results should be considered as pre-
liminary given the small sample size, the number of dropouts, and
single-arm open label design of the study. Therefore, these fMRI
findings should be confirmed in additional studies in a larger
sample with a double blind randomized control trial with smok-
ers and non-smokers. Further studies are needed to understand
the relationship of varenicline to glutamate and brain networks
dynamics. The quantification of glutamate with 1H-MRS is dif-
ficult. Glutamate, glutamine (the major metabolite of synaptic
glutamate), and GABA have overlapping peaks that are difficult
to resolve at low magnetic field strength. A single peak termed
Glx containing the three peaks is usually reported. The Glx peak
cannot be simply equated with glutamatrgic neurotransmission
as extracellular and vesicular glutamate represents only a small
fraction of total brain glutamate. A technical strength of our
study that partially compensates for this is the use of an echo
time of 80ms which appears to optimize the glutamate signal
by diminishing macromolecule contribution and reducing glu-
tamine contribution to the spectra (Bottomley, 1987; Schubert
et al., 2004). Finally, the comparisons between completers vs.
non-completers were based on small groups.
In conclusion, the results of this study suggest two possible
mechanisms of action for varenicline: reduction in glutamate lev-
els in ACC and shifts in BOLD activities between large scale brain
networks. Understanding the mechanism of action of antismok-
ing drugs is key to identifying novel and more efficacious com-
pounds for smoking cessation. These findings are preliminary.
Further studies are needed to assess the definitive mechanisms of
varenicline.
ACKNOWLEDGMENTS
We want to thank Dr. Richard Kennedy and Dr. Edwin Cook
for statistical assistance as well as Dr. Jan A. den Hollander for
expertise in MRS acquisition. This work was supported by an
investigator-initiated grant from Pfizer.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fphar.
2014.00158/abstract
www.frontiersin.org July 2014 | Volume 5 | Article 158 | 9
Wheelock et al. Varenicline effects on cingulate cortex
REFERENCES
Allen, R. P., Barker, P. B., Horska, A., and Earley, C. J. (2013). Thalamic
glutamate/glutamine in restless legs syndrome: increased and related to
disturbed sleep. Neurology 80, 2028–2034. doi: 10.1212/WNL.0b013e31
8294b3f6
Ashburner, J. (2007). A fast diffeomorphic image registration algorithm.
Neuroimage 38, 95–113. doi: 10.1016/j.neuroimage.2007.07.007
Azizian, A., Nestor, L. J., Payer, D., Monterosso, J. R., Brody, A. L., and London, E.
D. (2010). Smoking reduces conflict-related anterior cingulate activity in absti-
nent cigarette smokers performing a Stroop task. Neuropsychopharmacology 35,
775–782. doi: 10.1038/npp.2009.186
Bauer, J., Pedersen, A., Scherbaum, N., Bening, J., Patschke, J., Kugel, H., et al.
(2013). Craving in alcohol-dependent patients after detoxification is related
to glutamatergic dysfunction in the nucleus accumbens and the anterior
cingulate cortex. Neuropsychopharmacology 38, 1401–1408. doi: 10.1038/npp.
2013.45
Benowitz, N. L. (2008). Clinical pharmacology of nicotine: implications for under-
standing, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83,
531–541. doi: 10.1038/clpt.2008.3
Bottomley, P. A. (1987). Spatial localization in NMR spectroscopy in vivo. Ann. N.Y.
Acad. Sci. 508, 333–348.
Botvinick, M., Nystrom, L. E., Fissell, K., Carter, C. S., and Cohen, J. D. (1999).
Conflict monitoring versus selection-for-action in anterior cingulate cortex.
Nature 402, 179–181.
Brody, A. L., Mandelkern, M. A., London, E. D., Childress, A. R., Lee, G. S., Bota,
R. G., et al. (2002). Brain metabolic changes during cigarette craving. Arch. Gen.
Psychiatry 59, 1162–1172. doi: 10.1001/archpsyc.59.12.1162
Cole, D. M., Beckmann, C. F., Long, C. J., Matthews, P. M., Durcan, M. J., and
Beaver, J. D. (2010). Nicotine replacement in abstinent smokers improves cogni-
tive withdrawal symptoms with modulation of resting brain network dynamics.
Neuroimage 52, 590–599. doi: 10.1016/j.neuroimage.2010.04.251
Cox, L. S., Tiffany, S. T., and Chirsten, A. G. (2001). Evaluation of the brief ques-
tionnaire of smoking urges (QSU-brief) in laboratory and clinical.Nicotine Tob.
Res. 3, 7–16. doi: 10.1080/14622200020032051
Craig, A. D. (2002). How do you feel? Interoxeption: the sense of the physiological
condition of the body. Nat. Rev. Neurosci. 3, 655–666. doi: 10.1038/nrn894
Craig, A. D. (2009). Emotional moments across time: a possible neural basis for
time perception in the anterior insula. Philos. Trans. R. Soc. Lond. B Biol. Sci.
364, 1933–1942. doi: 10.1098/rstb.2009.0008
Ettinger, U., Williams, S. C., Patel, D., Michel, T. M., Nwaigwe, A., Caceres, A., et al.
(2009). Effects of acute nicotine on brain function in healthy smokers and non-
smokers: estimation of inter-individual response heterogeneity. Neuroimage 45,
549–561. doi: 10.1016/j.neuroimage.2008.12.029
Fiore, M. C., Jaen, C. R., Baker, T. B., Baily, W. C., Benowitz, N. L., Curry, S. J., et al.
(2008). Treating Tobacco Use and Dependence: 2008 Update. Rockvill, MD: US
Department of Healthy and Human Services; Public Health Service.
Fox, M. D., Snyder, A. Z., Vincent, J. L., Corbetta, M., Van Essen, D. C., and Raichle,
M. E. (2005). The human brain is intrinsically organized into dynamic, anticor-
related functional networks. Proc. Natl. Acad. Sci. U.S.A. 102, 9673–9678. doi:
10.1073/pnas.0504136102
Franklin, T., Wang, Z., Suh, J. J., Hazan, R., Cruz, J., Li, Y., et al. (2011). Effects of
varenicline on smoking cue-triggered neural and craving responses. Arch. Gen.
Psychiatry 68, 516–526. doi: 10.1001/archgenpsychiatry.2010.190
Friston, K. J., Buechel, C., Fink, G. R., Morris, J., Rolls, E., and Dolan, R. J. (1997).
Psychophysiological andmodulatory interactions in neuroimaging.Neuroimage
6, 218–229.
Gallinat, J., and Schubert, F. (2007). Regional cerebral glutamate concentra-
tions and chronic tobacco consumption. Pharmacopsychiatry 40, 64–67. doi:
10.1055/s-2007-970144
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al.
(2006). Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs
sustained- release bupropion and placebo for smoking cessation. JAMA 296,
47–55. doi: 10.1001/jama.296.1.47
Hahn, B., Ross, T. J., Yang, Y., Kim, I., Huestis, M. A., and Stein, E.
A. (2007). Nicotine enhances visuospatial attention by deactivating areas
of the resting brain default network. J. Neurosci. 27, 3477–3489. doi:
10.1523/JNEUROSCI.5129-06.2007
Harding, I. H., Solowij, N., Harrison, B. J., Takagi, M., Lorenzetti, V., Lubman, D.
I., et al. (2012). Functional connectivity in brain networks underlying cognitive
control in chronic cannabis users. Neuropsychopharmacology 37, 1923–1933.
doi: 10.1038/npp.2012.39
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., and Fagerström, K. (1991).
The Fagerström Test for Nicotine Dependence: a revision of the Fagerström
Tolerance Questionnaire. Br. J. Addict. 86, 1119–1127.
Hoerst, M., Weber-Fahr, W., Tunc-Skarka, N., Ruf, M., Schmahl, C., Ende, G.
(2010). Correlation of glutamate levels in the anterior cingulate cortex with
self-reported impulsivity in patients with borderline personality disorder and
healthy controls. Arch. Gen. Psychiatry 67, 946–954. doi: 10.1001/archgenpsy-
chiatry.2010.93
Hopfinger, J. B., Buonocore, M. H., and Mangun, G. R. (2000). The neural
mechanisms of top-down attentional control. Nat. Neurosci. 3, 284–291. doi:
10.1038/72999
Hughes, J. R., and Hatsukami, D. (1986). Signs and symptoms of tobacco with-
drawal. Arch. Gen. Psychiatry 43, 289–294.
Kalivas, P. W., Lalumiere, R. T., Knackstedt, L., and Shen, H. (2009). Glutamate
transmission in addiction. Neuropharmacology 56(Suppl. 1), 169–173. doi:
10.1016/j.neuropharm.2008.07.011
Kalivas, P. W., and O’Brien, C. (2008). Drug addiction as a pathol-
ogy of staged neuroplasticity. Neuropsychopharmacology 33, 166–180. doi:
10.1038/sj.npp.1301564
Kelly, A. M., Uddin, L. Q., Biswal, B. B., Castellanos, F. X., and Milham, M.
P. (2008). Competition between functional brain networks mediates behav-
ioral variability. Neuroimage 39, 527–537. doi: 10.1016/j.neuroimage.2007.
08.008
Kim, S. G., and Ogawa, S. (2012). Biophysical and physiological origins of blood
oxygenation level-dependent fMRI signals. J. Cereb. Blood Flow Metab. 32,
1188–1206. doi: 10.1038/jcbfm.2012.23
Koob, G. F., and Volkow, N. D. (2010). Neurocircuitry of addiction.
Neuropsychopharmacology 35, 217–238. doi: 10.1038/npp.2009.110
Loughead, J., Ray, R., Wileyto, E. P., Ruparel, K., Sanborn, P., Siegel, S., et al.
(2010). Effects of the alpha4beta2 partial agonist varenicline on brain activity
and working memory in abstinent smokers. Biol. Psychiatry 67, 715–721. doi:
10.1016/j.biopsych.2010.01.016
Maloku, E., Kadriu, B., Zhubi, A., Dong, E., Pibiri, F., Satta, R., et al. (2011).
Selective alpha4beta2 nicotinic acetylcholine receptor agonists target epige-
netic mechanisms in cortical GABAergic neurons. Neuropsychopharmacology
36, 1366–1374. doi: 10.1038/npp.2011.21
Markou, A. (2008). Review. Neurobiology of nicotine dependence. Philos. Trans. R.
Soc. Lond. B Biol. Sci. 363, 3159–3168. doi: 10.1098/rstb.2008.0095
Mashhoon, Y., Janes, A. C., Jensen, J. E., Prescot, A. P., Pachas, G., Renshaw, P.
F., et al. (2011). Anterior cingulate proton spectroscopy glutamate levels differ
as a function of smoking cessation outcome. Prog. Neuropsychopharmacol. Biol.
Psychiatry. 35, 1709–1713. doi: 10.1016/j.pnpbp.2011.05.006
Mason, M. F., Norton, M. I., Van Horn, J. D., Wegner, D. M., Grafton, S. T., and
Macrae, C. N. (2007). Wandering minds: the default network and stimulus -
independent thought. Science 315, 393–395. doi: 10.1126/science.1131295
Naqvi, N. H., Rudrauf, D., Damasio, H., and Bechara, A. (2007). Damage to
the insula disrupts addiction to cigarette smoking. Science 315, 531–534. doi:
10.1126/science.1135926
Niendam, T. A., Laird, A. R., Ray, K. L., Dean, Y. M., Glahn, D. C., and Carter,
C. S. (2012). Meta-analytic evidence for a superordiante cognitive control net-
work subserving diverse executive functions. Cogn. Affect. Behav. Neurosci. 12,
241–268. doi: 10.3758/s13415-011-0083-5
Paterson, N. E., and Markou, A. (2005). The metabotropic glutamate receptor
5 antagonist MPEP decreased break points for nicotine, cocaine and food
in rats. Psychopharmacology (Berl.) 179, 255–261. doi: 10.1007/s00213-004-
2070-9
Paterson, N. E., Semenova, S., Gasparini, F., and Markou, A. (2003). The mGluR5
antagonist MPEP decreased nicotine self-administration in rats and mice.
Psychopharmacology (Berl.) 167, 257–264. doi: 10.1007/s00213-003-1432-z
Payne, T. J., and Crews, K. M. (2012). Brief Treatment of the Tobacco Dependent
Patient: A Training Program for Healthcare Providers. Jackson, MS: University of
Mississippi Medical Center Printing Office.
Radloff, L. S. (1977). The CES-D Scale: a self-report depression scale for research
in the general population. Appl. Pyschol. Meas. 1, 385–401.
Raichle, M. E., and Snyder, A. Z. (2007). A default mode of brain function: a brief
history of an evolving idea. Neuroimage 37, 1083–1090. discussion: 1097–1089.
doi: 10.1016/j.neuroimage.2007.02.041
Frontiers in Pharmacology | Neuropharmacology July 2014 | Volume 5 | Article 158 | 10
Wheelock et al. Varenicline effects on cingulate cortex
Reid, M. A., Stoeckel, L. E., White, D. M., Avsar, K. B., Bolding, M. S., Akella,
N. S., et al. (2010). Assessments of function and biochemistry of the ante-
rior cingulate cortex in schizophrenia. Biol. Psychiatry 68, 625–633. doi:
10.1016/j.biopsych.2010.04.013
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L.
A., et al. (2007). Pharmacological profile of the alpha4beta2 nicotinic acetyl-
choline receptor partial agonist varenicline, an effective smoking cessation aid.
Neuropharmacology 52, 985–994. doi: 10.1016/j.neuropharm.2006.10.016
Romigi, A., and Vitrani, G. (2013). Improvement of restless legs syndrome by
varenicline as antismoking treatment. J. Clin. Sleep Med. 9, 1089–1090. doi:
10.5664/jcsm.3092
Schubert, F., Gallinat, J., Seifert, F., and Rinneberg, H. (2004). Glutamate
concentrations in human brain using single voxel proton magnetic
resonance spectroscopy at 3 Tesla. Neuroimage 21, 1762–1771. doi:
10.1016/j.neuroimage.2003.11.014
Sonuga-Barke, E. J., and Castellanos, F. X. (2007). Spontaneous attentional fluctua-
tions in impaired states and pathological conditions: a neurobiological hypoth-
esis. Neurosci. Biobehav. Rev. 31, 977–986. doi: 10.1016/j.neubiorev.2007.02.005
Sutherland, M. T., Carroll, A. J., Salmeron, B. J., Ross, T. J., Hong, L. E., and
Stein, E. A. (2013). Down-regulation of amygdala and insula functional circuits
by varenicline and nicotine in abstinent cigarette smokers. Biol. Psychiatry 74,
538–546. doi: 10.1016/j.biopsych.2013.01.035
Sutherland, M. T., McHugh, M. J., Pariyadath, V., and Stein, E. A. (2012). Resting
state functional connectivity in addiction: lessons learned and a road ahead.
Neuroimage 62, 2281–2295. doi: 10.1016/j.neuroimage.2012.01.117
Tonstad, S., Tonnesen, P., Hajek, P., Williams, K. E., Billing, C. B., and Reeves, K. R.
(2006). Effect of maintenance therapy with varenicline on smoking cessation: a
randomized controlled trial. JAMA 296, 64–71. doi: 10.1001/jama.296.1.64
Torrubia, R., Avila, C., Molto, J., and Caseras, X. (2001). The Sensitivity to
Punishment and Sensitivity to Reward Questionnaire (SPSRQ) as a meausre of
Bray’s anxiety and impulsivity dimensions. Pers. Individ. Dif. 31, 837–862. doi:
10.1016/S0191-8869(00)00183-5
Umhau, J. C., Memenan, R., Schwandt, M. L., Singley, E., Lifshitz, M., Doty, L., et al.
(2010). Effect of acamprosate on magnetic resonance spectroscopy measures
of central glutamate in detoxified alcohol-dependent individuals. Arch. Gen.
Psychiatry 67, 1070–1077. doi: 10.1001/archgenpsychiatry.2010.125
van Wageningen, H., Jorgensen, H. A., Specht, K., and Hugdahl, K.
(2010). A 1H-MR spectroscopy study of changes in glutamate and
glutamine (Glx) concentrations in frontal spectra after administra-
tion of memantine. Cereb. Cortex 20, 798–803. doi: 10.1093/cercor/
bhp145
Weissman, D. H., Gopalakrishnan, A., Hazlett, C. J., and Woldorff, M. G. (2005).
Dorsal anterior cingulate cortex resolves conflict from distracting stimuli by
boosting attention toward relevant events. Cereb. Cortex 15, 229–237. doi:
10.1093/cercor/bhh125
Conflict of Interest Statement: The corresponding author received medication
and investigator-initiated financial support provided by Pfizer. Pfizer provided no
input into the design, collection, analysis, or interpretation of the data, or writing
of the manuscript. Pfizer did provide approval of a poster presented at a local
conference (UAB-AU Neuroimaging retreat 2012). The information approved by
Pfizer for the poster is also found in this manuscript. The authors declare that the
research was conducted in the absence of any commercial or financial relationships
that could be construed as a potential conflict of interest.
Received: 10 April 2014; accepted: 18 June 2014; published online: 08 July 2014.
Citation: WheelockMD, ReidMA, To H,White DM, Cropsey KL and Lahti AC (2014)
Open label smoking cessation with varenicline is associated with decreased glutamate
levels and functional changes in anterior cingulate cortex: preliminary findings. Front.
Pharmacol. 5:158. doi: 10.3389/fphar.2014.00158
This article was submitted to Neuropharmacology, a section of the journal Frontiers in
Pharmacology.
Copyright © 2014 Wheelock, Reid, To, White, Cropsey and Lahti. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org July 2014 | Volume 5 | Article 158 | 11
